BeiGene Q3 Global Revenue Hits $1.9B, Full-Year Guidance Raised to $6.9B-$7.0B

Cointime update: BeiGene reported third-quarter 2026 global revenue of $1.9 billion, up 34% year over year, with Brukinsa (zanubrutinib) contributing $1.4 billion, also up 34%. GAAP diluted earnings per American Depositary Share were $3.28, while non-GAAP diluted EPS came in at $4.59. The company raised its full-year 2026 total revenue guidance to $6.9 billion to $7.0 billion, with GAAP operating profit of $1.2 billion to $1.3 billion.